BrainStorm Partners With Dana-Farber for NurOwn(TM) Production in Phase II ALS Clinical Trial

BrainStorm Partners With Dana-Farber for NurOwn(TM) Production in Phase II ALS 
Clinical Trial 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 04/08/13
--  BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer
of adult stem cell technologies for neurodegenerative diseases,
announced today that Dana-Farber Cancer Institute ("Dana-Farber") has
entered into an agreement to provide cGMP-compliant clean room
facilities for production of BrainStorm's NurOwn(TM) stem cell
candidate during its upcoming Phase II ALS trial in the USA. The
Company's Phase II trial, to be launched in the second half of 2013
pending FDA approval, will be conducted at Massachusetts General
Hospital ("MGH"), the University of Massachusetts ("UMass") Hospital
and the Mayo Clinic. The Connell and O'Reilly Cell Manipulation Core
Facility at Dana-Farber will produce NurOwn for the MGH and UMass
Hospital clinical sites. 
"We are pleased to begin this work that could be of great value to
ALS patients," said Dr. Jerome Ritz, Director of the Connell and
O'Reilly Cell Manipulation Core Facility at Dana-Farber and Professor
of Medicine at Harvard Medical School. "This is exactly the kind of
service that the facility was set up to provide. We appreciate the
opportunity to work closely with BrainStorm and colleagues at MGH and
UMass to advance cell therapy solutions for difficult diseases." 
"Today's announcement brings us another step closer to developing a
potentially effective treatment option for patients with ALS," said
Alon Natanson, Chief Executive Officer of BrainStorm. "With plans in
place at leading institutions like MGH, UMass, Mayo Clinic and
Dana-Farber, we believe the company is well positioned to conduct our
next Phase II trial at the highest clinical standards and with
maximum efficiency." 
Results of a Phase I/II clinical study of BrainStorm's NurOwn
technology in patients with ALS were recently presented at the 65th
Annual Meeting of the American Academy of Neurology. The data
demonstrated a significantly slower decline in overall clinical and
respiratory function, as measured by the ALS Functional Rating Score
(ALSFRS-R) and Forced Vital Capacity (FVC) score respectively, in the
six patients that received an intrathecal injection of the cells in
the s
ix months following treatment, as compared to the three months
preceding treatment.  
About NurOwn(TM)
 NurOwn is an autologous, adult stem cell therapy
technology that differentiates bone marrow-derived mesenchymal stem
cells into specialized, neuron-supporting cells. These
neuron-supporting cells (known as "MSC-NTF" cells) secrete
neurotrophic, or nerve-growth, factors for PROTECTION of existing
motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT
of nerve-muscle interaction. The ability to differentiate mesenchymal
stem cells into MSC-NTF cells, and confirmation of their activity and
potency before transplantation, makes NurOwn a first-of-its-kind
approach for treating neurodegenerative diseases. More information
about NurOwn(TM) can be found at 
About BrainStorm Cell Therapeutics, Inc. 
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged
in the development of first-of-its-kind adult stem cell therapies
derived from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at 
Safe Harbor Statement - Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
BrainStorm Cell Therapeutics Inc. 
Mr. Alon Natanson 
Phone: +972-3-9236384  
LifeSci Advisors, LLC
Michael Rice 
Founding Partner
Press spacebar to pause and continue. Press esc to stop.